309915-12-6

309915-12-6 structure

Name: Talmapimod hydrochloride
Chemical Name: Talmapimod hydrochloride
CAS Number: 309915-12-6
Molecular Formula: C₂₇H₃₁Cl₂FN₄O₃
Molecular Weight: 549.46
Catalog: Signaling Pathways MAPK/ERK Pathway p38 MAPK
Create Date: 2020-06-01 17:57:27
Modify Date: 2024-01-10 23:11:19
Talmapimod (SCIO-469) hydrochloride is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod hydrochloride shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs[1][2][3].

Name	Talmapimod hydrochloride

Description	Talmapimod (SCIO-469) hydrochloride is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod hydrochloride shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK
Target	p38α:9 nM (IC50) p38β:90 nM (IC50)
In Vitro	Talmapimod (SCIO-469) hydrochloride (100-200 nM; 1 hour) inhibits phosphorylation of p38 MAPK in MM cells[1]. Talmapimod hydrochloride inhibits LPS-induced TNF-a production in human whole blood[2]. Talmapimod hydrochloride decreases constitutive p38alpha MAPK phosphorylation of both 5T2MM and 5T33MM cells[3]. Western Blot Analysis[1] Cell Line: MM.1S, U266, RPMI8226, MM.1R, and RPMI-Dox40 cell lines Concentration: 100, 200 nM Incubation Time: 1 hour Result: Strongly inhibits phosphorylation of p38 MAPK.
In Vivo	Talmapimod hydrochloride (10-90 mg/kg; P.o.; twice daily orally for 14 days) dose-dependently reduced tumor growth and also dose-dependently reduced weight of the palpable tumors at termination[4]. Animal Model: Six-week-old male triple immune-deficient BNX mice (RPMI-8226 MM palpable tumors)[4] Dosage: 10, 30, 90 mg/kg Administration: P.o.; twice daily orally for 14 days Result: Dose-dependently reduced tumor growth.
References	[1]. Hideshima T et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18, 23(54), 8766-76. [2]. Navas T, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma. 2008 Oct;49(10):1963-75. [3]. Vanderkerken K et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease,reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res. 2007 May 15;67(10):4572-7. [4]. Medicherla S, et al. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma. Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.

Molecular Formula	C₂₇H₃₁Cl₂FN₄O₃
Molecular Weight	549.46

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

309915-12-6	1406-14-0
6138-79-0	127228-87-9
143851-98-3	929-73-7
65546-09-0	1135280-78-2
56-99-5	1406-02-6
2137536-24-2	2580201-06-3
2408970-64-7	2229454-67-3
2229020-23-7	2172599-68-5
2172487-53-3	2172588-87-1
2172475-83-9	2172583-97-8